Delcath Systems (NASDAQ:DCTH - Get Free Report) is expected to be releasing its earnings data before the market opens on Thursday, March 6th. Analysts expect Delcath Systems to post earnings of ($0.10) per share and revenue of $14.96 million for the quarter. Persons interested in participating in the company's earnings conference call can do so using this link.
Delcath Systems Trading Up 1.6 %
DCTH stock traded up $0.22 during mid-day trading on Friday, hitting $14.17. The stock had a trading volume of 193,450 shares, compared to its average volume of 320,418. The stock has a market capitalization of $453.07 million, a price-to-earnings ratio of -10.50 and a beta of 0.86. Delcath Systems has a 1-year low of $3.70 and a 1-year high of $16.97. The company has a fifty day moving average of $14.24 and a 200 day moving average of $11.49.
Analysts Set New Price Targets
A number of research firms have recently commented on DCTH. HC Wainwright reaffirmed a "buy" rating and set a $22.00 price objective on shares of Delcath Systems in a report on Tuesday, January 14th. Craig Hallum lifted their target price on shares of Delcath Systems from $18.00 to $21.00 and gave the stock a "buy" rating in a report on Friday, January 17th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $22.25.
Read Our Latest Stock Report on DCTH
Delcath Systems Company Profile
(
Get Free Report)
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Further Reading
Before you consider Delcath Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Delcath Systems wasn't on the list.
While Delcath Systems currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
